Industry News
Excerpt from the Press Release: PHILADELPHIA — David C. Fajgenbaum, MD, MBA, MSc, an assistant professor of Translational Medicine & Human Genetics and director of the Center for Cytokine Storm Treatment & Laboratory at the Perelman School of Medicine at the University of Pennsylvania, was awarded $1 million by the Parker Institute for Cancer Immunotherapy…
Read More
Excerpt from the Press Release: WARMINSTER, Pa. and WALTHAM, Mass. and MUNICH, Germany, April 01, 2021 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (NASDAQ: ABUS), X-Chem, Inc. (X-Chem) and Proteros biostructures GmbH (Proteros) announced today that they have entered into a discovery research and license agreement focused on the discovery of novel inhibitors targeting the SARS-CoV-2…
Read More
Excerpt from the Press Release: SAN DIEGO, March 31, 2021 (GLOBE NEWSWIRE) — Solid tumors comprise about 90% of all newly diagnosed cancer cases and cancer deaths according to an annual report from the National Cancer Institute. Despite the relative “ease” of surgical resection of such tumors, there lies significant risk in the recurrence of…
Read More
Excerpt from the Press Release: The preclinical study found CureVac’s candidate, dubbed CVnCoV, protected mice against COVID-19 in a virus challenge study with the B.1.351 variant of the SARS-CoV-2 virus. The variant, first identified in South Africa, bears certain mutations that make it more contagious than the original virus. It marks the first mouse challenge…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ — Exacis Biotherapeutics Inc., a development-stage immuno-oncology company working to democratize access to the most advanced and effective cancer treatments, today announced several important steps in the preclinical development of its ExaNK™ engineered NK cell-therapy candidates. ExaNK™ cells are generated from induced pluripotent stem cells (iPSCs) that are made using mRNA-based cell-reprogramming and gene-editing…
Read More
Excerpt from the Press Release: SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) — Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase 2 clinical trial of OTO-313 in patients with unilateral tinnitus. The randomized, double-blind, placebo-controlled Phase 2 study will enroll approximately…
Read More
Excerpt from the Article: Meissa Vaccines’ intranasal live attenuated chimeric virus-based vaccine for SARS-CoV-2 (and its variants) recently was cleared for Phase I trials, which will start at the end of March. Unlike other live attenuated virus vaccines, it employs codon deoptimization to evoke a stronger-than-usual immune response. If approved, it holds the potential of…
Read More
Excerpt from the Article: Simultaneous use of a deep-learning based detection (DLD) system improves a radiologist’s accuracy in identifying major abnormalities on chest X-rays, a new study has found. While the efficacy of artificial intelligence (AI) algorithms as a second reader has been well established in previous studies, providers included in those investigations have read…
Read More
Excerpt from the Press Release: SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today updated positive results from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS). This ongoing study (MSC-COV-101) is a single arm, non-randomized Phase 1b study of the safety and preliminary efficacy of COVI-MSCs administered every other day for…
Read More Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalization. This interim safety and efficacy analysis was based on 32,449 participants accruing 141 symptomatic cases of COVID-19. The trial had…
Read More